Although the proportion of EGFR mutant patients was much larger in our Chinese cohort (47.3% vs 15.5%), which consists with previous studies [1, 2], exon 20 insertions accounted for a smaller proportion compared to FM cohort in EGFR mutant NSCLC (4.8% vs. 11.7%, p < 0.001) [17]. Here, EGFR is linked to non-small cell lung carcinoma.